Physicians' Academy for Cardiovascular Education

Diabetic dyslipidemia: the pro-atherogenic role of CETP

Slides (presentation) - Oct. 18, 2011

Prof. John Betteridge
University College London
United Kingdom

To view presentation, click on slides below

Diabetic dyslipidemia: The pro-atherogenic role of CETP and future use of CETP inhibitors
Diabetes and Cardiovascular Disease: Time To Act!
Risk of Fatal and Non-fatal CHD in Men with Type 2 Diabetes
Numbers of People (106) with Diabetes for 2000 and 2010
Survival Post-MI in Diabetic and Non-diabetic Men and Women
Temporal Mortality Trends
Plaque Characteristics
UKPDS: Risk Factors for MI.
Atherogenic Dyslipidaemia ( Metabolic Syndrome, Type 2 Diabetes)
Clinical Manifestations of Central Obesity
Lipoprotein Metabolism in Insulin Resistance and Type 2 Diabetes
Characteristics of LDL Subclasses
The Absolute Concentration of LDL-C Can be Misleading in Subjects with Small, Dense LDL.
LDL Subfractions “Control” vs Patient with Insulin Resistance
Statins:The Evidence Base.
CARDS: Collaborative AtoRvastatin Diabetes Study
Median Lipid Levels by Treatment
Median Lipid Levels by Treatment
Cumulative Hazard for Primary Endpoint
Heart Protection Study: Diabetes Subgroups With/Without CHD or Other CVD
LDL-C and change in percent atheroma volume in IVUS studies
Atherogenic Dyslipidaemia
HPS Diabetic Cohort
Role of CETP in Lipoprotein Metabolism
Dysfunctional HDL in Diabetes
How to Increase HDL?
ILLUMINATE: Recent Post Hoc Analysis:
How to Increase HDL?
How to Increase HDL?
Long term Effects of Pioglitazone on HDL-Cholesterol and Triglycerides in CVD Trials
Intravascular Ultrasound of Coronary Arteries Determining the Atheroma Area
Pre Treatment
Lancet 2009; 374:126.
Aleglitazar: Summary of Cardiometabolic Effects
Aleglitazar: Ongoing Trial – ALECARDIO
The Atherogenic Lipid Profile
High LDL-C and low HDL-C Are Associated With Increased CHD Risk

Download teaching slides

Share this page with your colleagues and friends: